AtaiBeckley

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch AtaiBeckley and buy or sell other stocks, ETFs, and their options commission-free!

About ATAI

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. 

CEO
Srinivas G. Rao
CEOSrinivas G. Rao
Employees
54
Employees54
Headquarters
Amstelveen, Noord-Holland
HeadquartersAmstelveen, Noord-Holland
Founded
2020
Founded2020
Employees
54
Employees54

ATAI Key Statistics

Market cap
2.67B
Market cap2.67B
Price-Earnings ratio
-5.09
Price-Earnings ratio-5.09
Dividend yield
Dividend yield
Average volume
3.73M
Average volume3.73M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$6.75
52 Week high$6.75
52 Week low
$1.15
52 Week low$1.15

Stock Snapshot

AtaiBeckley(ATAI) stock is priced at $7.35, giving the company a market capitalization of 2.67B. It carries a P/E multiple of -5.09.

AtaiBeckley(ATAI) stock opened on 2026-09-14 at —. The price climbed to — and dipped to —.

AtaiBeckley(ATAI) shares are trading with a volume of 0, against a daily average of 3.73M.

In the last year, AtaiBeckley(ATAI) shares hit a 52-week high of $6.75 and a 52-week low of $1.15.

In the last year, AtaiBeckley(ATAI) shares hit a 52-week high of $6.75 and a 52-week low of $1.15.

People also own

Based on the portfolios of people who own ATAI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.